BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 11577374)

  • 1. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
    Ally R; Schürmann D; Kreisel W; Carosi G; Aguirrebengoa K; Dupont B; Hodges M; Troke P; Romero AJ;
    Clin Infect Dis; 2001 Nov; 33(9):1447-54. PubMed ID: 11577374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
    de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
    Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.
    de Wet NT; Bester AJ; Viljoen JJ; Filho F; Suleiman JM; Ticona E; Llanos EA; Fisco C; Lau W; Buell D
    Aliment Pharmacol Ther; 2005 Apr; 21(7):899-907. PubMed ID: 15801925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
    Kullberg BJ; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Rex JH; Cleary JD; Rubinstein E; Church LW; Brown JM; Schlamm HT; Oborska IT; Hilton F; Hodges MR
    Lancet; 2005 Oct 22-28; 366(9495):1435-42. PubMed ID: 16243088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
    Krause DS; Simjee AE; van Rensburg C; Viljoen J; Walsh TJ; Goldstein BP; Wible M; Henkel T
    Clin Infect Dis; 2004 Sep; 39(6):770-5. PubMed ID: 15472806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
    Hamza OJ; Matee MI; Brüggemann RJ; Moshi MJ; Simon EN; Mugusi F; Mikx FH; van der Lee HA; Verweij PE; van der Ven AJ
    Clin Infect Dis; 2008 Nov; 47(10):1270-6. PubMed ID: 18840077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
    Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
    J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole treatment for less-common, emerging, or refractory fungal infections.
    Perfect JR; Marr KA; Walsh TJ; Greenberg RN; DuPont B; de la Torre-Cisneros J; Just-Nübling G; Schlamm HT; Lutsar I; Espinel-Ingroff A; Johnson E
    Clin Infect Dis; 2003 May; 36(9):1122-31. PubMed ID: 12715306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspofungin: new indication. No progress in invasive candidiasis.
    Prescrire Int; 2004 Apr; 13(70):48-9. PubMed ID: 15148956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.
    Viljoen J; Azie N; Schmitt-Hoffmann AH; Ghannoum M
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1671-9. PubMed ID: 25561337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
    Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
    Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model.
    González GM; Portillo OJ; Uscanga GI; Andrade SE; Robledo M; Rodríguez C; Elizondo M
    J Antimicrob Chemother; 2009 Sep; 64(3):571-3. PubMed ID: 19570754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
    Sambatakou H; Dupont B; Lode H; Denning DW
    Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.
    Vazquez JA; Skiest DJ; Nieto L; Northland R; Sanne I; Gogate J; Greaves W; Isaacs R
    Clin Infect Dis; 2006 Apr; 42(8):1179-86. PubMed ID: 16575739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
    Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
    J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS.
    Hegener P; Troke PF; Fätkenheuer G; Diehl V; Ruhnke M
    AIDS; 1998 Nov; 12(16):2227-8. PubMed ID: 9833866
    [No Abstract]   [Full Text] [Related]  

  • 20. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.